More and more people are being diagnosed with cancer each day, and up to 1 in 8 women will be diagnosed with breast cancer during their lifetime. Whilst treatments for breast cancer have advanced greatly over the years there is still an unmet clinical need for patients diagnosed with late stage metastatic cancer with only approximately 8% of patients surviving for more than 5 years following diagnosis.
Understanding patient tolerability in early clinical trials is a key aspect of drug development. New innovative research on PROACT (Patient Reported Opinions About clinical Tolerability), investigating the use of patient focused technology has been shared more widely through a recent research article.
The Cancer Centre at Guy’s will open to the public in September 2016 after many years of planning and design. Hospital staff and patients have worked side by side with architects to create it. The centre combines a caring environment with the latest scientific advances to provide the best possible treatment to people who have been diagnosed with cancer.
The DI-B4 Phase I trial of anti-CD19 monoclonal antibody for patients with advanced CD19-positive indolent B-cell malignancies (led by Chief Investigator Andrew Davies at Southampton ECMC) finished recruiting in July. The aim of the trial was to establish the biological effects and maximum tolerated dose of the low-fuscosylated anti-CD19 IgG1 monoclonal antibody DI-B4.
Scientists at Edinburgh-Dundee ECMC have uncovered important information about how ovarian cancer becomes resistant to certain treatments.
The researchers, based in Dundee, discovered that a gene called ABCB1, which is known to play a role in resistance to the chemotherapy drug paclitaxel in ovarian cancers, also causes resistance to other ovarian cancer treatments.
The ECMC Secretariat is delighted to announce the launch of applications for the upcoming Quinquennium. Existing ECMC locations are invited to apply for status for the 2017-22 period, and continue their contribution to a leading Network of early-phase clinical trials.
The ECMC Network strives to push the boundaries of cancer care, by delivering novel and personalised treatments that target a wide range of cancer types across both adult and paediatric specialties.